Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $5.67 million. The enterprise value is $8.74 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, after market close.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 9.45 million shares outstanding. The number of shares has increased by 222.35% in one year.
| Current Share Class | 9.45M |
| Shares Outstanding | 9.45M |
| Shares Change (YoY) | +222.35% |
| Shares Change (QoQ) | +17.29% |
| Owned by Insiders (%) | 9.23% |
| Owned by Institutions (%) | 18.37% |
| Float | 7.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.11 |
| Forward PS | 0.16 |
| PB Ratio | 11.35 |
| P/TBV Ratio | 12.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 10.37.
| Current Ratio | 1.40 |
| Quick Ratio | 0.53 |
| Debt / Equity | 10.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.24 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -49.47% |
| Return on Invested Capital (ROIC) | -284.71% |
| Return on Capital Employed (ROCE) | -289.39% |
| Revenue Per Employee | $408,570 |
| Profits Per Employee | -$123,925 |
| Employee Count | 93 |
| Asset Turnover | 1.85 |
| Inventory Turnover | 2.64 |
Taxes
In the past 12 months, Biofrontera has paid $20,000 in taxes.
| Income Tax | 20,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.39% in the last 52 weeks. The beta is 0.30, so Biofrontera's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -39.39% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 40.57 |
| Average Volume (20 Days) | 262,326 |
Short Selling Information
The latest short interest is 119,292, so 1.26% of the outstanding shares have been sold short.
| Short Interest | 119,292 |
| Short Previous Month | 37,741 |
| Short % of Shares Out | 1.26% |
| Short % of Float | 1.68% |
| Short Ratio (days to cover) | 0.97 |
Income Statement
In the last 12 months, Biofrontera had revenue of $38.00 million and -$11.53 million in losses. Loss per share was -$1.69.
| Revenue | 38.00M |
| Gross Profit | 20.24M |
| Operating Income | -16.29M |
| Pretax Income | -23.08M |
| Net Income | -11.53M |
| EBITDA | -15.97M |
| EBIT | -16.29M |
| Loss Per Share | -$1.69 |
Full Income StatementBalance Sheet
The company has $1.79 million in cash and $4.86 million in debt, giving a net cash position of -$3.07 million or -$0.33 per share.
| Cash & Cash Equivalents | 1.79M |
| Total Debt | 4.86M |
| Net Cash | -3.07M |
| Net Cash Per Share | -$0.33 |
| Equity (Book Value) | 469,000 |
| Book Value Per Share | 0.05 |
| Working Capital | 4.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.06 million and capital expenditures $44,000, giving a free cash flow of -$11.02 million.
| Operating Cash Flow | -11.06M |
| Capital Expenditures | 44,000 |
| Free Cash Flow | -11.02M |
| FCF Per Share | -$1.17 |
Full Cash Flow StatementMargins
Gross margin is 53.26%, with operating and profit margins of -42.87% and -30.33%.
| Gross Margin | 53.26% |
| Operating Margin | -42.87% |
| Pretax Margin | -30.28% |
| Profit Margin | -30.33% |
| EBITDA Margin | -42.02% |
| EBIT Margin | -42.87% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -222.35% |
| Shareholder Yield | -222.35% |
| Earnings Yield | -203.34% |
| FCF Yield | -194.40% |
Analyst Forecast
The average price target for Biofrontera is $2.75, which is 358.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.75 |
| Price Target Difference | 358.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 25.81% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
Biofrontera has an Altman Z-Score of -10.64 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.64 |
| Piotroski F-Score | 3 |